5 / 27
OS (3 years’ minimum follow-up)
Felip E. et al. ESMO 2017 1301PD
CI = confidence interval; HR = hazard ratio
292
194
148
112
82
58
49
39
7
0
290
195
112
67
46
35
26
16
1
0
135
86
57
38
31
26
21
16
8
0
137
69
33
17
11
10
8
7
3
0
CheckMate 057 (non-SQ NSCLC)
CheckMate 017 (SQ NSCLC)
No. of patients at risk
Nivolumab
Docetaxel
No. of patients at risk
Nivolumab
Docetaxel
0
6
12
18
24
30
36
42
48
54
Δ10%
Nivolumab (n = 135)
Docetaxel (n = 137)
1-y OS = 42%
2-y OS = 23%
3-y OS = 16%
1-y OS = 24%
2-y OS = 8%
3-y OS = 6%
HR (95% CI): 0.62 (0.48, 0.80)
100
80
60
40
20
0
OS (%)
Months
Δ18%
Δ15%
0
6
12
18
24
30
36
42
48
54
Months
1-y OS = 51%
2-y OS = 29%
3-y OS = 18%
1-y OS = 39%
2-y OS = 16%
3-y OS = 9%
Nivolumab (n = 292)
Docetaxel (n = 290)
HR (95% CI): 0.73 (0.62, 0.88)
100
80
60
40
20
0
OS (%)
Δ12%
Δ13%
Δ9%